151751-Najiba-Chargi

283 Systemic therapy: skeletal muscle mass changes and chemoradiotherapy Table 4. (Continued) Univariate analysis Multivariate analysis HR (95% CI) p-value HR (95% CI) p-value Tumor localization Oral cavity Oropharynx Nasopharynx Hypopharynx Larynx Paranasal sinus Unknown primary Ref. 2.64 (1.72-4.04) 2.52 (1.26-5.04) 0.72 (0.39-1.31) 2.88 (1.21-6.85) 1.36 (0.60-3.09) 0.71 (0.10-5.21) <0.01 <0.01 0.28 0.02 0.46 0.74 Ref. 2.36 (1.16-4.8) 3.6 (0.9-14.1) 0.55 (0.21-1.46) 1.81 (0.37-8.9) 0.82 (0.2-3.47) 0 (0-9.999) 0.02 0.07 0.23 0.47 0.79 0.98 HPV-status Negative Positive Unknown Ref. 1.25 (0.62-2.49) 1.45 (0.59-3.55) 0.53 0.42 CRT setting Primary Adjuvant Ref. 0.46 (0.32-0.68) <0.01 Ref. 0.39 (0.2-0.77) <0.01 Dose-limiting toxicity No Yes Ref. 1.04 (0.73-1.47) 0.84 Cumulative chemotherapy dose <300mg ≥300mg Ref. 0.63 (0.42-0.97) 0.03 Ref. 0.57 (0.29-1.1) 0.09 Weight loss during CRT None < 10% ≥ 10% Ref. 1.45 (0.94-2.23) 1.76 (0.91-3.42O) 0.09 0.09 Legend table 4: Abbreviations: SMM: skeletal muscle mass, HR: hazard ratio, SD: standard deviation BMI: body-mass index, ACE-27: adult comorbidity evaluation-27, ECOG: Easter Cooperative Oncology Group, HPV: human papilloma virus, TNM: tumor, node, metastasis, CRT: chemoradiotherapy SURVIVAL: OVERALL SURVIVAL AND DISEASE-FREE SURVIVAL During the follow-up period from November 2011 till May 2019, 86 (37%) patients died, and 72 (31%) patients developed a recurrence. The median OS was 22 months (IQR 12-39) and the median DFS was 19months (IQR 9-35). Of the patients that died, 43 (50%) patients experienced a loss in SMM, 36 (42%) patients had stable SMM changes, and 7 (8%) patients gained SMM after treatment. Of the patients that developed a recurrence during follow up, 36 (50%) patients had a loss in SMM, 31 (43%) patients had stable SMM changes, and 5 (7%) patients gained SMM. Although half of the patients who died or had a recurrence during follow-up experienced a loss in SMM, in univariate Cox regression analysis no prognostic value of loss in SMM for OS nor DFS were found. Using stable or gain in SMM changes as the reference group, HRs for SMM loss were 0.9 (95% CI 0.6-1.4) and 0.8 (95% CI 0.5-1.3) respectively. Figure 1 shows the Kaplan-Meier OS and DFS curves for patients with loss in SMM versus no loss in SMM (stable 15